Contents Vol. 16, 1998
A. Bykova, Maria Helena Ornellas de Souza, Grzegorz Dworacki, Antônio Augusto Ornellas(Hospital do Câncer III), Galina V. Shurin(University of Health Sciences Antigua), Mario Mandalà(University of Perugia), Matthias Stoss, Virgínia Pires, Edward M. Barksdale(University of Pittsburgh Medical Center), Fabrizio Fabbrizzi, Luisa Giani, Michael T. Lotze(University of Pittsburgh), Yaniv Sherer, EmilyClare P. Baker, V. Gerein, Sergey G. Kremlev(Jackson Laboratory), Eliane Barbosa Esteves, Sukh Mahendra Singh(Banaras Hindu University), J Zeromski, Vineeta Khare(Medical University of Vienna), Yehuda Shoenfeld(Weizmann Institute of Science), Robert W. Gorter, Jeff Terryberry, A. Razzaque Ahmed(Emory University), Mércia Mendes Campos, Jan Sikora, Yair Levy, Luca Fumagalli, James B. Peter, Guo Qiu Shen, Franco Rovelli, Marcos Antônio Maurício Scheiner, Robert Evans, Ronald B. Herberman(National Cancer Institute), Ajit Sodhi, Ellen Peter, Paolo Lissoni, Andrei I. Chapoval(Human Genome Sciences (United States))
Cited by 0
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k